Last reviewed · How we verify
ITI-214
At a glance
| Generic name | ITI-214 |
|---|---|
| Sponsor | Intra-Cellular Therapies, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure (PHASE1, PHASE2)
- Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease (PHASE1, PHASE2)
- Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ITI-214 CI brief — competitive landscape report
- ITI-214 updates RSS · CI watch RSS
- Intra-Cellular Therapies, Inc. portfolio CI